TLR7 and influenza: In this work, we have sought to engineer PNP hydrogels to improve humoral immune response to influenza vaccines comprising HA and a potent TLR7/8a adjuvant, (1‐(4‐[aminomethyl]benzyl)‐2‐(ethoxymethyl)‐1H‐imidazo[4,5‐c]quinolin‐4‐amine) (Figure 1), which is a derivative of Resiquimod (R848).